AdaptHealth (NASDAQ:AHCO) Stock, Quote.Headers.trade-ideas

AdaptHealth

AdaptHealth Corp is engaged in providing patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services. It focuses on providing; sleep therapy equipment, supplies, and related services (including CPAP and bi-PAP services) to individuals suffering from obstructive sleep apnea (OSA), medical devices and supplies to patients for the treatment of diabetes (including continuous glucose monitors (CGM and insulin pumps), home medical equipment to patients discharged from acute care and other facilities, oxygen and related chronic therapy services in the home, and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy and nutritional supply needs.

News

Health Care

Small Cap

Markets

Trading Ideas

General

AHCO

Philips (NYSE: PHG) is leaving no stone unturned to bolster its patient monitoring solutions portfolio on the back of recent collaborations.
In this regard, the company partnered with smartQare to integrate the latter&#39;s viQtor solution into its clinical patient monitoring platforms.


Philips (PHG) Boosts Patient Monitoring With SmartQare Deal

Penny Stocks

Intraday Update

Movers

ALPP

AULT

BBAI

BEAM

BIOR

BLUE

CARG

CDXS

CLDI

CLVT

CXAI

DNLI

DORM

EGIO

ELWS

FEAM

Hims & Hers Health, Inc. Class A Common Stock

HIMS

HSII

IFBD

JANX

LGND

LUNR

MICS

NERV

NRXP

NVCR

PEGY

PRGO

PRIM

PRST

PTLO

PUBM

PYXS

SOUN

STGW

STRL

TBIO

TMDX

TREE

TWKS

VKTX

WDAY

WETG

Shares of  Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings.

Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

MGNI

NCLH

U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Tuesday.

Norwegian Cruise Line Posts Strong Sales, Joins Hims &amp; Hers Health, Sterling Infrastructure And Other Big Stocks Moving Higher On Tuesday

AdaptHealth Corp

<p>H&amp;R Block (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRB#NYSE">HRB</a>) has outperformed the market over the past 5 years by 2.77% on an annualized basis producing an average annual return of 15.37%. Currently, H&amp;R Block has a market capitalization of $7.95 billion. </p>
<p><strong>Buying $1000 In HRB:</strong> If an investor had bought $1000 of HRB stock 5 years ago, it would be worth <strong>$2,049.30</strong> today based on a price of $56.95 for HRB at the time of writing.</p>
<h3>H&amp;R Block's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722029438_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,000 Today

<p>Apollo Global Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) has outperformed the market over the past 10 years by 5.7% on an annualized basis producing an average annual return of 16.62%. Currently, Apollo Global Management has a market capitalization of $69.51 billion. </p>
<p><strong>Buying $1000 In APO:</strong> If an investor had bought $1000 of APO stock 10 years ago, it would be worth <strong>$4,546.33</strong> today based on a price of $122.16 for APO at the time of writing.</p>
<h3>Apollo Global Management's Performance Over Last 10 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722029433_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$1000 Invested In Apollo Global Management 10 Years Ago Would Be Worth This Much Today

<p>Citigroup  analyst Atif Malik   maintains Teradyne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) with a Buy and lowers the price target from $185 to $162.</p>


Price Target

Analyst Ratings

Citigroup Maintains Buy on Teradyne, Lowers Price Target to $162

<p>During the last three months, 5 analysts shared their evaluations of Puma Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBYI#NASDAQ">PBYI</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $7.0, a high estimate of $7.00, and a low estimate of $7.00. The average price target has stayed the same, reflecting a consistent view from analysts. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722027698_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>A comprehensive examination of how financial experts perceive Puma Biotechnology is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Puma Biotechnology. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Puma Biotechnology compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Puma Biotechnology's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Puma Biotechnology's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PBYI/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Puma Biotechnology analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About Puma Biotechnology</h2>
<p>Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.</p>
<h3>A Deep Dive into Puma Biotechnology's Financials</h3>
<p><strong>Market Capitalization:</strong> Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.</p>
<p><strong>Revenue Challenges:</strong> Puma Biotechnology's revenue growth over 3 months faced difficulties. As of 31 March, 2024, the company experienced a decline of approximately <strong>-17.07%</strong>. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Puma Biotechnology's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-11.0%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Puma Biotechnology's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>-9.22%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Puma Biotechnology's ROA excels beyond industry benchmarks, reaching <strong>-2.17%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Puma Biotechnology's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>2.17</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


PBYI

Where Puma Biotechnology Stands With Analysts

<p>During the last three months, 10 analysts shared their evaluations of Lennox Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LII#NYSE">LII</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Lennox Intl, presenting an average target of $581.9, a high estimate of $675.00, and a low estimate of $517.00. This upward trend is apparent, with the current average reflecting a 7.66% increase from the previous average price target of $540.50.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722027675_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Lennox Intl. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$550.00</td>
<td>$517.00</td>
</tr>
<tr>
<td>Tommy Moll</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$675.00</td>
<td>$675.00</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$572.00</td>
<td>$566.00</td>
</tr>
<tr>
<td>Jeffrey Hammond</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$600.00</td>
<td>$515.00</td>
</tr>
<tr>
<td>Timothy Wojs</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$610.00</td>
<td>$505.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$517.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Joe Ritchie</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$575.00</td>
<td>$507.00</td>
</tr>
<tr>
<td>Joseph O'Dea</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$570.00</td>
<td>$550.00</td>
</tr>
<tr>
<td>Gautam Khanna</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$600.00</td>
<td>$550.00</td>
</tr>
<tr>
<td>Joseph O'Dea</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$550.00</td>
<td>$520.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Lennox Intl. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Lennox Intl compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Lennox Intl's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>For valuable insights into Lennox Intl's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/LII/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Lennox Intl analyst ratings.</strong></a></p>
<h2>Delving into Lennox Intl's Background</h2>
<p>Lennox International manufactures and distributes heating, ventilating, air conditioning, and refrigeration products to replacement (75% of sales) and new construction (25% of sales) markets. In fiscal 2023, residential HVAC was 68% of sales and commercial HVAC and Heatcraft refrigeration was 32% of sales. The company goes to market with multiple brands, but Lennox is the company's flagship HVAC brand. The Texas-based company is focused on North America after the sale of its European HVAC and refrigeration businesses in late 2023.</p>
<h3>Unraveling the Financial Story of Lennox Intl</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Lennox Intl showcased positive performance, achieving a revenue growth rate of <strong>2.81%</strong> as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>16.95%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Lennox Intl's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>51.98%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Lennox Intl's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>7.92%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Lennox Intl's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>2.72</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


10 Analysts Have This To Say About Lennox Intl

<p>Taiwan Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) has outperformed the market over the past 10 years by 12.34% on an annualized basis producing an average annual return of 23.26%. Currently, Taiwan Semiconductor has a market capitalization of $837.03 billion. </p>
<p><strong>Buying $1000 In TSM:</strong> If an investor had bought $1000 of TSM stock 10 years ago, it would be worth <strong>$7,815.64</strong> today based on a price of $161.40 for TSM at the time of writing.</p>
<h3>Taiwan Semiconductor's Performance Over Last 10 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722027659_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$1000 Invested In Taiwan Semiconductor 10 Years Ago Would Be Worth This Much Today

<p>Canadian Natural Res (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNQ#NYSE">CNQ</a>) has outperformed the market over the past 5 years by 9.75% on an annualized basis producing an average annual return of 22.36%. Currently, Canadian Natural Res has a market capitalization of $73.53 billion. </p>
<p><strong>Buying $100 In CNQ:</strong> If an investor had bought $100 of CNQ stock 5 years ago, it would be worth <strong>$279.38</strong> today based on a price of $34.42 for CNQ at the time of writing.</p>
<h3>Canadian Natural Res's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722027654_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Here's How Much You Would Have Made Owning Canadian Natural Res Stock In The Last 5 Years

<p>Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Betterware de Mexico SAPI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWMX#NYSE">BWMX</a>) in the last three months.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $22.5, with a high estimate of $22.50 and a low estimate of $22.50. Consistency is reflected as the current average remains at the same level as the previous average price target. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722027642_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Betterware de Mexico SAPI. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Betterware de Mexico SAPI. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Betterware de Mexico SAPI compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Betterware de Mexico SAPI's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into Betterware de Mexico SAPI's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/BWMX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Betterware de Mexico SAPI analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Discovering Betterware de Mexico SAPI: A Closer Look</h2>
<p>Betterware de Mexico SAPI de CV is a direct-to-consumer selling company. The company operates through two business segments: the home organization products (Betterware segment or BWM segment) and the beauty and personal care products (B and PC) (JAFRA segment). The Betterware's segment is divided into different categories based on the type of products it sells and includes, kitchen and food preservation, home solutions, bathroom, laundry &amp; cleaning, tech and mobility, and bedroom and wellness products. The JAFRA's segment is divided into fragrance, color, skincare, and toiletries products. The company generates a majority of its revenue from the Beauty and personal care (B&amp;PC) (JAFRA segment). Geographically, key revenue for the company is derived from Mexico.</p>
<h3>A Deep Dive into Betterware de Mexico SAPI's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Betterware de Mexico SAPI's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately <strong>10.36%</strong>. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Betterware de Mexico SAPI's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>8.16%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Betterware de Mexico SAPI's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>19.7%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Betterware de Mexico SAPI's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>2.68%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>3.6</strong>, Betterware de Mexico SAPI adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


BWMX

Critical Insights From Betterware de Mexico SAPI Analyst Ratings: What You Need To Know

<p>Canaccord Genuity  analyst Dalton Baretto   maintains MAG Silver (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MAG#TSX">MAG</a>) with a Buy and raises the price target from C$22 to C$23.</p>


TSX:MAG

Canaccord Genuity Maintains Buy on MAG Silver, Raises Price Target to C$23

<p>Canaccord Genuity  analyst Mike Mueller   maintains Baytex Energy (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BTE#TSX">BTE</a>) with a Buy and raises the price target from C$6.25 to C$6.5.</p>


TSX:BTE

Canaccord Genuity Maintains Buy on Baytex Energy, Raises Price Target to C$6.5

<p>First Cap (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCAP#NASDAQ">FCAP</a>) reported quarterly earnings of $0.85 per share. This is a 3.66 percent increase over earnings of $0.82 per share from the same period last year.</p>


Earnings

FCAP

First Cap Q2 EPS $0.85 Up From $0.82 YoY

Asset Sales

Johnson Controls International: Purchase Deal Says Robert Bosch Will Pay Co Termination Fee Of $300M If Purchase Agreement Is Terminated

<p><strong>PayPal Holdings's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NYSE">PYPL</a>) short percent of float has fallen 4.83% since its last report. The company recently reported that it has <strong>20.55 million shares sold short</strong>, which is 1.97% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 2.04 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>PayPal Holdings Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722026721_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for PayPal Holdings has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing PayPal Holdings's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, PayPal Holdings's peer group average for short interest as a percentage of float is 5.82%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

PYPL

How Is The Market Feeling About PayPal Holdings?

<p><strong>Owens-Corning's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OC#NYSE">OC</a>) short percent of float has risen 10.34% since its last report. The company recently reported that it has <strong>1.49 million shares sold short</strong>, which is 2.24% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 2.27 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>Owens-Corning Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722026716_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Owens-Corning has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Owens-Corning's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Owens-Corning's peer group average for short interest as a percentage of float is 4.00%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Looking Into Owens-Corning's Recent Short Interest

<p><strong>Kohl's's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) short percent of float has risen 4.82% since its last report. The company recently reported that it has <strong>40.73 million shares sold short</strong>, which is 51.14% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 8.49 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>Kohl's Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722026711_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Kohl's has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Kohl's's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Kohl's's peer group average for short interest as a percentage of float is 9.12%, which means the company has <strong>more</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


(KSS) - Analyzing Kohl's's Short Interest

<p><a href="https://www.ft.com/content/d67a6325-d316-4bb8-80e3-1d51429b3393">https://www.ft.com/content/d67a6325-d316-4bb8-80e3-1d51429b3393</a></p>
<p>Howard Schultz, the former Starbucks chief executive, is opposing a potential settlement between the company and activist investor Elliott Investment Management, in the latest sign of tension at the world's largest coffee chain. The quasi-founder of Starbucks has made his opposition to an Elliott settlement known to some board members, said people familiar with the matter. Schultz had criticised its leadership publicly in recent months despite no longer having a formal role at the company. He remains Starbucks's sixth-largest shareholder, with a holding of about $1.6bn. Elliott, known for being an aggressive investor, has built a sizeable minority stake in the $86bn company and has privately pushed for change in recent weeks, including board representation, in an attempt to revive Starbucks' lacklustre performance. Schultz and Elliott have not been in contact over this matter, one person said. Companies under pressure from activists such as Elliott often seek to negotiate agreements with them rather than face a public fight, but the status of any settlement discussions between Starbucks and Elliott remain unclear. "Howard left the board a year ago and in his limited contact with the board since, his input has always focused on the values and culture of Starbucks as the primary driver of success and performance," a person close to Schultz said. The billionaire former coffee machine salesman led the company three separate times — for about 14 years starting in 1986, then again from 2008 to 2017, and most recently as interim CEO from 2022 to 2023.&nbsp; He was succeeded as CEO last year by Laxman Narasimhan, who joined from UK-based consumer health and hygiene group Reckitt. Schultz remains chair emeritus but left the company's board and has said he does not have access to financial information.</p>
<p><br />Schultz, who has said he has no interest in returning as CEO, has remained vocal on the sidelines. This spring he criticised the company's performance on LinkedIn, penning an open letter that said senior leaders and board members needed "to spend more time with those who wear the green apron". He also made an appearance on business podcast Acquired in June, speaking about the history of Starbucks and his recommendations for management. "It hasn't been a great year for Starbucks," he said. "In fairness to Laxman, there's a lot of external issues that have contributed to the pressure, like on every company. But the company has not executed the way that I think it should have." "If the company is doing a drift towards mediocrity, I hold leadership, and the board responsible for that," he said later in the three-hour podcast.<br /><br />Starbucks's share price has fallen about 20 per cent since the start of 2024. The company cut its financial guidance in January and again in April, when it reported a 4 per cent decline in quarterly comparable store sales that was the first such drop since late 2020. It is due to announce results for its fiscal third quarter on Tuesday. Starbucks has made changes to its board over the past year. Three new members, including the CEOs of YouTube and T-Mobile, Neal Mohan and Mike Sievert, joined earlier this year. This spring, Microsoft CEO Satya Nadella left the board. Spokespeople for Schultz, Starbucks and Elliott declined to comment.</p>


Legal

Management

SBUX

'Howard Schultz Opposes Starbucks Settlement With Activist Investor Elliott' - Financial Times

Offerings

ALRN

Aileron Therapeutics Got Into Equity Distribution Agreement, May Offer & Sell Shares Of Our Common Stock From Time To Time Of Up To $50M

WIIM

VTVT

vTv Therapeutics shares are trading lower after the company announced the FDA has placed a clinical hold on the cadisegliatin clinical program which includes the ongoing CATT1 phase 3 trial in type 1 diabetes.

vTv Therapeutics Shares Resume Trade

<p>Paragon Technologies, Inc. ("Paragon"), a diversified holding company and a large shareholder of Ocean Power Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OPTT#NYSE">OPTT</a>), ("Company" or "OPT"), issues the following statement to OPT shareholders:</p>
<p>On July 5, OPT filed a proxy statement calling for a special meeting of shareholders on August 30, 2024, asking shareholders to approve increasing the Company's authorized shares to 200 million, up from 100 million.</p>
<p><strong>On July 25, 2025, OPT announced Fiscal 2024 financial results revealing that it lost $27.4 million in fiscal 2024 versus $26.3 million in fiscal 2023.</strong></p>


OPTT

PGNT

Paragon Technologies Recommends Ocean Power Shareholders Vote AGAINST Its Plan To Increase Its Authorized Shares By 100M

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>Finding investing opportunities in the market might be challenging. Nevertheless, three equities stick out due to their ability to yield&nbsp;large&nbsp;profits during volatility. The first one sticks out due to its strong financial performance, which is characterized by considerable sales, margins, and profitability increases. The company&rsquo;s growth trajectory and durability against market uncertainty make it a desirable investment for those looking for stability and upside potential in the electronic manufacturing services industry.</p>



<p>Moreover, the second one exhibits tenacity in the face of difficulties. It showcases skillful cash flow management and advancements in deleveraging initiatives. Even though the company has encountered challenges, it can control risks and uphold financial discipline. This highlights its growth potential and offers investors interested in the healthcare distribution industry a compelling opportunity.</p>



<p>Finally, the third one shows encouraging growth potential in the healthcare technology sector. A consistent increase in chronic care enrollment fuels this. The pattern indicates long-term income potential as well as the efficacy of the company&rsquo;s solutions, making it a desirable option for investors hoping to profit from the growing virtual care market.</p>



<h2>Celestica (CLS)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/04/cls1600-300x169.png" alt="Person holding cellphone with website of Canadian electronics company Celestica Inc. (CLS) on screen in front of logo. Focus on center of phone display. Unmodified photo."><div>Source: T. Schneider / Shutterstock.com</div></div><p><strong>Celestica&rsquo;s</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/cls-stock-quote/"><strong>CLS</strong></a></span>) first-quarter 2024 revenue of&nbsp;<a href="https://corporate.celestica.com/static-files/e5734a8b-faa0-4b9c-9a7f-3d5992421970" target="_blank">$2.21 billion</a>&nbsp;had a solid 20% boost.&nbsp;This&nbsp;is over the company&rsquo;s $1.84 billion revenue during the same period in 2023. The Communications, Consumer, and Enterprise (<a href="https://investorplace.com/stock-quotes/ccs-stock-quote/"><strong>CCS</strong></a>) segment has a solid performance, reporting an impressive 38% year-over-year (YoY) increase. It was the main driver of the company&rsquo;s top-line gain. Moreover, the revenue increase indicates Celestica&rsquo;s capacity to seize market openings and satisfy client demand, especially in areas like&nbsp;<a href="https://corporate.celestica.com/static-files/e5734a8b-faa0-4b9c-9a7f-3d5992421970" target="_blank">AI/ML computing&nbsp;</a>solutions and hyperscale clients.</p>



<p>Additionally, the Advanced Technology Solutions (<a href="https://investorplace.com/stock-quotes/ats-stock-quote/"><strong>ATS</strong></a>) division&nbsp;<a href="https://finance.yahoo.com/news/celestica-inc-nyse-cls-q1-130024241.html" target="_blank">has a 4.7%&nbsp;</a>segment margin in the first quarter of 2024.&nbsp;This&nbsp;is up from 4.4% at the same time in 2023, despite a minor 3% fall in sales YoY. Notably, the ATS segment&rsquo;s Aerospace and Defense (A&amp;D) division demonstrated a robust double-digit revenue increase YoY,&nbsp;highlighting the segment&rsquo;s durability and development potential.</p>



<p>Overall, Celestica&rsquo;s revenue from its capital equipment sector saw a little increase and stabilization compared to last year&rsquo;s quarter, suggesting a rebound and an optimistic market attitude in this particular category.</p>



<h2>Adapthealth (AHCO)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/08/healthcare_staffing1600-300x169.png" alt="Medicine and healthcare concept - team or group of doctors and nurses"><div>Source: Supavadee butradee / Shutterstock.com</div></div><p>Even with&nbsp;adversities like payments&nbsp;being delayed&nbsp;due to the Change Healthcare data breach, <strong>Adapthealth</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/ahco-stock-quote/"><strong>AHCO</strong></a></span>) could still produce&nbsp;<a href="https://adapthealth.com/2024/05/07/adapthealth-corp-announces-first-quarter-2024-results/" target="_blank">$49 million</a>&nbsp;in operating cash flow (Q1 2024). Even though this is less than the $140.2 million from Q1 2023, it nevertheless signifies Adapthealth&rsquo;s resiliency in managing cash flow against operation adversities. Despite obstacles, AdaptHealth&rsquo;s free cash flow projection for H1 2024 is unchanged. The company is projecting a free cash flow of at least<a href="https://adapthealth.com/2024/05/07/adapthealth-corp-announces-first-quarter-2024-results/" target="_blank">&nbsp;$55 million</a>. In short, the company has the fundamental capacity to deal with sporadic setbacks and preserve its stability.</p>



<p>Additionally, using a deleveraging strategy, the company has sharply lowered its consolidated debt levels and leverage ratios during the last 12 months. AdaptHealth executed a disciplined approach to debt reduction by continuing to pay down debt over minimum payments&nbsp;during the Change in Healthcare difficulties. </p>



<p>Finally, AdaptHealth reduced from 3.16 times at the end of 2023 to 3.12 times at the end of Q1 2024, with $25 million going toward debt repayment in Q1 2024 and an additional $15 million after the quarter&rsquo;s end. Therefore, these efforts to pay down debt are ongoing, strengthening its financial standing and lowering risk.</p>



<h2>Teladoc&nbsp; (TDOC)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/03/tdoc-stock-2-300x169.jpg" alt="The Teladoc logo through a magnifying glass."><div>Source: Postmodern Studio / Shutterstock.com</div></div><p>Enrollment in chronic care at <strong>Teladoc</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/tdoc-stock-quote/"><strong>TDOC</strong></a></span>) increased by a&nbsp;<a href="https://s21.q4cdn.com/672268105/files/doc_financials/2024/q1/FINAL-EPR.pdf" target="_blank">solid 9% YoY.</a> At the end of the first quarter of 2024, there were $1.12 million members enrolled. This expansion shows a growing need for Teladoc&rsquo;s chronic care solutions, which is good news for the company&rsquo;s product line and clientele. Thus, Teladoc&rsquo;s stable increase in chronic care membership strengthens long-term profitability and recurring revenue streams.</p>



<p>Moreover, Teladoc uses AI and data to improve client interaction and drive&nbsp;<a href="https://s21.q4cdn.com/672268105/files/doc_financials/2024/q1/FINAL-EPR.pdf" target="_blank">efficiency throughout&nbsp;</a>its business processes. The organization uses AI models in provider matching, enrollment optimization, and member engagement, among other areas of its operations. AI makes personalized consumer interactions easier, enhancing service delivery and boosting income.</p>



<p>Finally, Teladoc has successfully implemented a land and grow strategy, as seen by&nbsp;<a href="https://finance.yahoo.com/news/teladoc-health-inc-nyse-tdoc-142426299.html" target="_blank">the roughly 2.2 million</a>&nbsp;new members who have joined during the last quarter. The company&rsquo;s primary strategy is cross-selling to current customers; cross-selling accounted for two-thirds of all bookings in the first quarter. Therefore, future cross-selling and product penetration have a lot of potential, thanks to Teladoc&rsquo;s growing membership base.</p>



<p><em>On the date of publication, Yiannis Zourmpanos did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.</em></p>
<div><p>Yiannis Zourmpanos is the founder of Yiazou Capital Research, a stock-market research platform designed to elevate the due diligence process through in-depth business analysis.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/05/3-high-potential-stocks-to-buy-at-rock-bottom-prices/">3 High-Potential Stocks to Buy at Rock-Bottom Prices</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

3 High-Potential Stocks to Buy at Rock-Bottom Prices

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AdaptHealth (AHCO – Research Report), Allogene Thera...

Analysts Are Bullish on Top Healthcare Stocks: AdaptHealth (AHCO), Allogene Therapeutics (ALLO)

Analyst Joanna Gajuk from Bank of America Securities maintained a Sell rating on AdaptHealth (AHCO – Research Report) and keeping the price target ...

AdaptHealth Growth Concerns Prompt Underperform Rating Amid Operational Challenges

Analyst Whit Mayo from Leerink Partners reiterated a Buy rating on AdaptHealth (AHCO – Research Report) and increased the price target to $14.00 fr...

AdaptHealth: A Strong Buy on Impressive EBITDA, Organic Growth, and Strategic Cost Management

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Pro Medicus Limited (PMCUF – Research Report), AdaptHealth (AHCO ...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Pro Medicus Limited (OtherPMCUF), AdaptHealth (AHCO) and Verastem (VSTM)

Patterson Companies: Something To Smile About

An update from AdaptHealth (AHCO) is now available. AdaptHealth Corp. stockholders have agreed to significant changes that will shape the company's...

AdaptHealth Enhances Governance and Expands Incentive Plan

Inspire Medical, ResMed decline following Lilly tirzepatide sleep apnea data

AdaptHealth (AHCO) has shared an announcement. AdaptHealth Corp. announced the upcoming resignation of its President, Joshua Parnes, effective Augu...

AdaptHealth Executive Transition and Board Chair Appointment

McKesson Corporation: An Interesting Health Giant With A Hidden Gem

ALLO

HSIC

INSP

PDCO

PETQ

PMCUF

PRVA

TDOC

VSTM

Press Releases

AdaptHealth Corp. to Participate in the BofA Securities 2024 Health Care Conference

AdaptHealth Corp. to Participate in the 2024 Leerink Partners Healthcare Crossroads Conference

AdaptHealth Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

AdaptHealth Corp. to Participate in the UBS Healthcare Services Cape Cod Summit

AdaptHealth Corp. to Participate in the Jefferies Global Healthcare Conference

AdaptHealth Corp. to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

The Portnoy Law Firm Announces Investigation of AdaptHealth Corp. (NASDAQ: AHCO)

AdaptHealth Corp. Announces Changes to Board of Directors and Management

AdaptHealth Corp. Announces Second Quarter 2024 Earnings Release Date and Conference Call

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

AdaptHealth

AdaptHealth (AHCO) Forecast

AdaptHealth (NASDAQ:AHCO) Stock, Quote.Headers.trade-ideas